Skip to main content
19 April 2025
Last updated:
Wednesday 16 April 2025
User account anon menu
Login
Register and subscribe
Search
Home
News
News
Appointments
Events
About MedNous
Who We Are
Editorial Board
Editorial Policy
Research Directory
Research Directory
Organisations
Interviewees
Terms
Topics
Contact Us
Contact Form
Menu
Breadcrumb
Home
Research Directory
Research Directory
Market Commentary: How risky are European biotechs?
Read more
The stately progress of antibiotics
Read more
Global oncology has many first-in-class compounds
Read more
Cheap capital gives rise to integrated pharma R&D
Read more
Commentary: Thought disruption in R&D discovery
Read more
Market Analysis: The outlook for European pharma
Read more
New risk capital for European companies
Read more
A strategy for treating traumatic brain injury
Read more
Treating the immune system, not the tumour
Read more
Debate heats up over germline editing
Read more
Pagination
First page
« First
Previous page
‹‹
…
Page
41
Page
42
Page
43
Page
44
Current page
45
Page
46
Page
47
Page
48
Page
49
…
Next page
››
Last page
Last »
Home
News
News
Appointments
Events
About MedNous
Who We Are
Editorial Board
Editorial Policy
Research Directory
Research Directory
Organisations
Interviewees
Terms
Topics
Contact Us
Contact Form